vitalia

Vitalia Interview #5 - Sebastian A. Brunemeier of ImmuneAGE Bio and General Partner at Healthspan Capital 

Navigating the Longevity Biotech Landscape: Insights from a Decade-Long Journey 

WHATCH THE INTERVIEW: https://youtu.be/cHdWif_Cwfg 

Starting and thriving in the longevity biotech industry isn't a cakewalk! We recently shared a captivating conversation with Sebastian, a seasoned entrepreneur who's spent the last 10 years diving deep into this field shares some key insights:

- Parallel Ventures: Running multiple companies simultaneously, leveraging synergies.

- Market Conditions: Navigating funding challenges amid fluctuating market interest.

- Longevity Medicine: The ongoing research and upcoming clinical breakthroughs.

- Current Treatments: Existing geroprotective drugs and supplements making waves.

-  Global Accessibility: How various jurisdictions affect drug accessibility and approval speed.

SUBSCRIBE: https://www.youtube.com/@Eisodos and

Vitalia Interview #5 - Sebastian A. Brunemeier of ImmuneAGE Bio and General Partner at Healthspan Capital 

Navigating the Longevity Biotech Landscape: Insights from a Decade-Long Journey 

WHATCH THE INTERVIEW: https://youtu.be/cHdWif_Cwfg 

Starting and thriving in the longevity biotech industry isn't a cakewalk! We recently shared a captivating conversation with Sebastian, a seasoned entrepreneur who's spent the last 10 years diving deep into this field shares some key insights:

- Parallel Ventures: Running multiple companies simultaneously, leveraging synergies.

- Market Conditions: Navigating funding challenges amid fluctuating market interest.

- Longevity Medicine: The ongoing research and upcoming clinical breakthroughs.

- Current Treatments: Existing geroprotective drugs and supplements making waves.

-  Global Accessibility: How various jurisdictions affect drug accessibility and approval speed.

SUBSCRIBE: https://www.youtube.com/@Eisodos and  https://paragraph.xyz/@eisodos.eth